CORCEPT THERAPEUTICS INC

CORT · XNAS

CIK 1088856fmd_0ZYJFWWD5AM0TWNR31VXC6CY84Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2000 to Sep 30, 2026, 76 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	81	159	251	306	354	366	402	482	675	761
Cost of revenue	2	4	5	6	6	5	5	6	11	13
Gross profit	79	156	246	301	348	361	396	476	664	748
Research and development	24	40	75	89	115	114	131	184	247	255
Selling, general and administrative	45	62	81	100	105	122	153	184	280	449
Total operating expenses	–	–	–	–	–	–	–	–	–	–
Operating income	10	53	89	112	128	124	113	107	137	45
Interest expense	2	–	–	–	–	–	–	–	–	–
Interest and investment income	–	–	–	–	–	–	–	–	–	–
Other non-operating income (expense)	–	–	–	–	–	1	4	17	25	22
Income before taxes	8	53	92	117	132	125	116	125	161	66
Income tax expense	0	(76)	17	22	26	12	15	18	20	(33)
Net income from continuing operations	8	129	75	94	106	113	101	106	141	100
Net income	8	129	75	94	106	113	101	106	141	100
Net income to common shareholders	–	–	–	–	106	113	101	105	140	98